← Trials/Trial dossier/NCT00637442

CASL-AD-01

UnknownPhase NA

Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD)

Lead sponsor

University Hospital, Bonn

Asset

Galantamine

Listed sites

Recruiting sites

Enrollment

estimated

Study population

Alzheimer’s disease

Key I/E criteria

•Alzheimer's disease•MRI contraindications excluded

Primary endpoint

•Cerebral perfusion

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00637442

Org study IDUniversity Bonn

Timeline

Milestones

Study start2008-02 (month precision)

Study first posted2008-03-18estimated

Last update posted2010-11-09estimated

Primary completion2010-12estimated (month precision)

Assets

Drug assets

Galantamine

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age50 Years

Maximum age80 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Possible Alzheimer's Disease according to ICD-10 and NINCDS-ADRDA

•Underwritten study consent

•No treatment with acetylcholinesterase inhibitors

•Mini-Mental-State Examination: 12-25 points

•Age: 50-80 Years

•Orale contraception for women of child-bearing age

Exclusion criteria

•Mental Disorders

•Other Diseases of the CNS

•Severe Illness

•Contraindication for MRI-Scan

•Contraindication for Galantamin (Reminyl retard®)

•Participation at other clinical trials

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Global cognition

Other (unclassified)

Behavior / neuropsychiatric

Global cognition

2 endpoints

Secondary/protocol endpoint

Change of Alzheimer Disease Assessment Scale, cognitive part (ADAScog)

Time frame:baseline, after 12 and 24 weeks

ADAS-Cog

descriptive

Secondary/protocol endpoint

Mini-Mental-Status-Examination (MMSE)

Time frame:baseline, after 12 and 24 weeks

Mini-Mental State Examination (MMSE)

categorical status, descriptive

Behavior / neuropsychiatric

1 endpoint

Secondary/protocol endpoint

Neuropsychiatric Inventory (NPI)

Time frame:baseline, after 12 and 24 weeks

Neuropsychiatric Inventory (NPI)

descriptive

Other (unclassified)

2 endpoints

Primary/protocol endpoint/low confidence

Cerebral perfusion

Time frame:baseline and after 12 weeks

descriptive

Secondary/protocol endpoint/low confidence

Alzheimer's Disease Functional Assessment and Change Scale (ADFACS)

Time frame:baseline, after 12 and 24 weeks

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.